Cogent Biosciences, Inc. Increase (Decrease) in Other Operating Liabilities
Cogent Biosciences, Inc. (COGT) reported Increase (Decrease) in Other Operating Liabilities of $57.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingLiabilities · last filed 2026-08-10
- Cogent Biosciences, Inc. increase (decrease) in other operating liabilities for the quarter ending 2026-06-30 was $28.00K, a 600.00% increase year-over-year.
- Cogent Biosciences, Inc. increase (decrease) in other operating liabilities for the quarter ending 2026-03-31 was $29.00K, a 480.00% increase year-over-year.
- Cogent Biosciences, Inc. increase (decrease) in other operating liabilities for the quarter ending 2025-12-31 was $13.00K.
- Cogent Biosciences, Inc. increase (decrease) in other operating liabilities for the quarter ending 2025-09-30 was $11.00K.
- Cogent Biosciences, Inc. increase (decrease) in other operating liabilities for fiscal 2025 was $33.00K.
- Cogent Biosciences, Inc. increase (decrease) in other operating liabilities for fiscal 2024 was $0.00.
- Cogent Biosciences, Inc. increase (decrease) in other operating liabilities for fiscal 2023 was $0.00.
| Period end | Increase (Decrease) in Other Operating Liabilities 3 month | Increase (Decrease) in Other Operating Liabilities 6 month | Increase (Decrease) in Other Operating Liabilities 9 month | Increase (Decrease) in Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $28.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $57.00K 10-Q · filed 2026-08-10 | $70.00K derived: sum of 3 quarters · filed 2026-08-10 | $81.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $29.00K 10-Q · filed 2026-05-05 | $42.00K derived: sum of 2 quarters · filed 2026-05-05 | $53.00K derived: sum of 3 quarters · filed 2026-05-05 | $57.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $13.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $24.00K derived: sum of 2 quarters · filed 2026-02-17 | $28.00K derived: sum of 3 quarters · filed 2026-08-10 | $33.00K 10-K · filed 2026-02-17 |
| 2025-09-30 | $11.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $15.00K derived: sum of 2 quarters · filed 2026-08-10 | $20.00K 10-Q · filed 2025-11-07 | |
| 2025-06-30 | $4.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $9.00K 10-Q · filed 2026-08-10 | ||
| 2025-03-31 | $5.00K 10-Q · filed 2026-05-05 | |||
| 2024-12-31 | $0.00 10-K · filed 2026-02-17 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |